ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$47.9M 137,083 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Cleerly, Inc.
Cleerly, Inc. reported $47,488,990.28 across General Payments, Research, and Ownership to 910 physicians and teaching hospitals across 1,305 transactions.
- $47.5M Top 10% payer
- All-tracks total
- 1,305 Above-median volume
- Transactions
- 910 Above-median reach
- Recipients
- −$300.9K
- General Payments vs PY2023
Cleerly, Inc. reported $47,488,990.28 across all CMS Open Payments tracks (General + Research + Ownership) to 910 physicians and teaching hospitals in Program Year 2024 - ranking #51 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $157,460.14, averaging $52.2K per recipient.
How Cleerly, Inc.'s $47.5M all-tracks total breaks down
Cleerly, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
53/100
Total payments
A
100/100
Transaction volume
F
19/100
Physician reach
F
17/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cleerly-inc Cleerly, Inc.
$47.5M · #51/1,925 · 0.3% industry · PY2024
- TOT $47.5M
- RANK #51
- SHARE 0.3%
- TXN 1,305
- RCP 910
- CAT 6
- GEN $157.5K
- ΔGEN −$300.9K
- TOP1 51.4%
- PY 2024
Volume peers
Nearest volume peer: ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($47.9M)
Cleerly, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Cleerly, Inc.'s CMS-reported General Payments decreased by $300.9K (−65.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: CLEERLY, INC.PY2024: Cleerly, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $458,392.37
- PY2024
- $157,460.14
What the Data Shows for Cleerly, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Cleerly, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 6-category general-payment breakdown below at $86.6K (55.0% of General Payments, 20 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 6 types of general payments, Cleerly, Inc.'s largest category was "Consulting Fee" at $86.6K - 55.0% of General Payments.
Cleerly, Inc. reports 6 general-payment categories - the top three are Consulting Fee (55.0%), Food and Beverage (29.1%), and Travel and Lodging (10.9%). The remaining 3 categories make up 4.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Cleerly, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $86.6K | 20 | 55.0% |
| Food and Beverage | $45.9K | 866 | 29.1% |
| Travel and Lodging | $17.2K | 11 | 10.9% |
| Compensation for Faculty or Speaker (Medical Education) | $4.5K | 1 | 2.9% |
| Compensation for Services Other Than Consulting | $3.1K | 9 | 2.0% |
| Debt Forgiveness | $42.58 | 3 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $108,893.29 (69.2%) of $157,460.14 in this company's General Payments records across 728 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cleerly, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Katharine Krol
$80,982.43 across 19 reported transactions
- 2
Andrew Baskin
$14,837.58 across 6 reported transactions
- 3
Matthew Budoff
$5,373.28 across 5 reported transactions
- 4
Farouc Jaffer
$4,500.00 across 1 reported transactions
- 5
Andrew Freeman
$3,200.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Cleerly, Inc. ranks #51 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #604 of 1,838 by HHI (top 33% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Stability Biologics, LLC : $235.6K total payments, HHI 2790
- Elekta Instrument AB : $354.2K total payments, HHI 2789
- Masimo Corporation : $2.6M total payments, HHI 2786
- Phadia AB : $11.9K total payments, HHI 2782
- Daiichi Sankyo Europe GmbH : $77.3K total payments, HHI 2769
- Pramand LLC : $22.8K total payments, HHI 2763
- Cleerly, Inc. (this company) : $157.5K total payments, HHI 2760
- Biodynamik, Inc : $23.6K total payments, HHI 2759
- Blue Sky Bio, LLC : $314.2K total payments, HHI 2746
- BTG International, Inc. : $670.8K total payments, HHI 2745
- Carbofix Orthopedics Inc : $49.7K total payments, HHI 2743
- Hyperfine Operations, Inc. : $52.4K total payments, HHI 2743
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cleerly, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cleerly, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cleerly, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Scientia Vascular
$46.9M 191 recipients
Compare payment profiles
Sumitomo Pharma America, Inc.
$48.1M 94,811 recipients
Compare payment profiles
Novo Nordisk AS
$49.2M 804 recipients
Compare payment profiles
Imperative Care, Inc
$45.6M 5,115 recipients
Compare payment profiles
Daiichi Sankyo Inc.
$45.4M 55,658 recipients
Compare payment profiles
Put this to use
Cleerly, Inc. ranks #51 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Cleerly, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Cleerly, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.